McKesson (MCK) Q4 FY26 earnings call: guidance and Q&A

Why is the FY27 RxTS revenue growth guidance slower than historical trends, and what are the expectations for GLP-1 growth within the prior authorization business, especially given the sequential decline in GLP-1 distribution revenue?

The variability in RxTS revenue growth is primarily due to the 3PL component (55% of revenue), which is impacted by timing of product launches and program launches. Despite revenue variability, the operating profit momentum is strong, reflecting high demand for technology services, including access programs for GLP-1s. GLP-1 solutions continue to see strong demand for prior authorization and affordability.

“If you think about the composition of revenue in that segment, as we've talked about over the last several years, the 3PL component of that business represents roughly 55% of total revenue. And as we've talked about, that business can vary quite significantly from quarter-to-quarter or year-to-year, driven by a number of factors.”

asked by Allen Lutz · answered by Britt Vitalone

Can you detail the organic vs. inorganic contributions to the Oncology and Multispecialty segment's FY27 revenue and operating profit guidance, and was there any impact from recent weather events?

Weather did not have a material impact on Q4 operations, as any demand impacts recovered within the quarter. The FY27 guidance for Oncology and Multispecialty reflects lapping the PRISM and Core Ventures acquisitions from Q1 FY26. Organic operating profit growth for the segment has been around 13%, and the guidance is at the upper end of the long-term target range, indicating strong underlying performance and successful integration of acquisitions.

“The organic performance of the segment is actually a little bit stronger than the guide reads. And we believe that the guide is strong, and it's actually at the upper end of the long-term target range.”

asked by Lisa Gill · answered by Britt Vitalone

What are the underlying utilization trends embedded in the North American Pharmaceutical segment guidance, and what are you seeing regarding specialty products, particularly to health systems?

Utilization trends have been stable, growing at a consistent rate for the past 2-3 years, which is factored into guidance. Specialty products continue to be a key growth driver due to innovation and strong market positioning. McKesson sees good growth in specialty products within health systems, leveraging its strong value proposition and long-standing presence in that channel.

“On the utilization front, we have seen stable utilization. And what I mean by that is year-over-year growth in utilization has been fairly constant now for several quarters. It's growing, albeit at a very stable rate really for the last, I'd say, 2, 3 years.”

asked by Erin Wilson · answered by Britt Vitalone

How is the pipeline changing for additional services within the MSO segment, especially with the onboarding of Core Ventures and Florida Cancer business, and where are the opportunities to expand services to drive incremental revenue and profit?

McKesson continues to expand its provider network by attracting oncologists and acquiring practices, leveraging its strong value proposition including investments in technology like ambient scribe to improve physician workflow. Opportunities lie in using technology to operate more efficiently, extract deeper insights for the Ontada business, and grow SCRI's ability to recruit for clinical trials, creating a virtuous cycle of value for physicians and manufacturers.

“We still think we have room to go just expanding the base of providers. And part of that expansion rests on the strong value proposition we have for providers, including the investments we're making in the practices themselves in things like ambient scribe, making the physician work experience, just focus more on patient care, less on administrative version that we think that helps address burnout.”

asked by Michael Cherny · answered by Brian Tyler

Given that over a third of the oncology market will be impacted by IRA or biosimilar transitions, how will the lower price of oncology drugs affect practice reimbursement (ASP) and McKesson's distribution margins, and will this augment long-term operating profit?

Biosimilars are seen as a 'win-win-win' for providers, patients, and distributors, offering lower costs and clinical choice. For distributors, biosimilars are expected to be somewhere between generics and brands in terms of margin. In the community setting, initial biosimilar launches can be good for practices, but sustaining ASP is key. McKesson's network effects, particularly in U.S. Oncology, allow for rapid and uniform adoption of biosimilars, creating value for manufacturers who compensate the GPO and distribution business.

“On the distribution side of the business, I think we've said that biosimilars will be for us somewhere between generics and the brands, and we continue to think that that's true.”

asked by Glen Santangelo · answered by Brian Tyler

Why does the FY27 free cash flow guidance imply a 13% reduction despite a 10% increase in adjusted operating profit, and what are the M&A priorities given strong share repurchases and continued investment?

The FY27 free cash flow guide is still strong, with FY26 being exceptional due to working capital timing. McKesson continues to invest in the business for future growth. Capital deployment priorities remain unchanged: first, strategic growth (organic and inorganic) with good financial returns; second, returning capital to shareholders through a growing dividend and share repurchases (planning $5 billion in FY27); and third, maintaining a strong investment-grade credit rating. The company has flexibility to shift capital between repurchases and growth opportunities.

“Our priority is to continue to grow the business and grow the business on strategy. We're able to find opportunities to advance our growth pillars with good financial returns. That would be the priority for us to do that.”

asked by Daniel Grosslight · answered by Britt Vitalone

Is the North America Pharma revenue guidance reflecting continued impact of price changes, and what is driving the operating profit growth being above the long-range plan targets?

North American Pharmaceutical revenue guidance accounts for lapping a large customer onboarding and Rite Aid revenue from the prior year, as well as the full-year impact of branded pricing manufacturer declines. Despite these factors, underlying organic revenue growth is strong. Operating profit growth is driven by strong specialty pharmaceutical growth, scaled market position, and significant operating efficiencies from network investments and infrastructure, leading to a 293 basis point improvement in consolidated operating expenses as a percentage of gross profit in FY26.

“When you look at those factors and you look at the underlying organic growth -- revenue growth of the business, it's actually quite strong when you look at it historically.”

asked by Charles Rhyee · answered by Britt Vitalone